## Vladimir Strugov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7688320/publications.pdf

Version: 2024-02-01

			2258059		2053705	
8	468		3		5	5
papers	citations		h-index		g-index	
8	8		8		6	80
all docs	docs cita	tions	times ra	nked	citing a	authors

#	Article	IF	CITATIONS
1	Impact of MRD Eradication on Survival Outcomes in CLL Patients with Different IGHV Mutation Status. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S273.	0.4	0
2	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 43-56.	10.7	448
3	Efficacy of Ibrutinib in the Treatment of First Early Relapses of CLL. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S216.	0.4	O
4	Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia. Annals of Hematology, 2018, 97, 2153-2161.	1.8	10
5	Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE. Blood, 2018, 132, 691-691.	1.4	8
6	Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia. Blood, 2018, 132, 5569-5569.	1.4	1
7	First Line BR in Chronic Lymphocytic Leukemia Patients: Interim Results of Russian Norma Trial. Blood, 2014, 124, 3332-3332.	1.4	1
8	Efficacy Of Different Therapeutic Approaches In Blastic Phase Of Chronic Myeloid Leukemia: Single Centre Experience. Blood, 2013, 122, 5173-5173.	1.4	O